InterAx

InterAx Biotech AG is a spinoff from ETH Zurich and the Paul Scherrer Institute. InterAx has built a unique drug discovery platform for identification of superior drug candidates. This technology allows for the integration of both, experimental and computational pharmacology, and is able to predict in vivo effects of drug candidates by analyzing complex experimental in vitro data sets.
Luca Zenone about Verve Ventures
Verve Ventures played a key role in the due diligence process and in the evaluation of the business case. VERVE Ventures has always been very open, extremely responsive and supportive, and keen to keep a close and thrustful relationship with the management team. In this collaborative setup, VERVE Ventures is clearly bringing additional value beyond the investment.
Founders / Management Luca Zenone, Aurélien Rizk
Sectors Health & Bio, Drug Discovery, Computational Pharmacology
Located in Switzerland
Co-Investors Falcon Ventures, AKB
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.